V. Memoli (Marseille, France)
Author Of 1 Presentation
47P - The impact of endocrine therapy and chemotherapy on quality of life 5 years after a breast cancer diagnosis: VICAN5 Survey
Abstract
Background
Endocrine therapy (ET) and chemotherapy (CHI) are among the adjuvant treatments for breast cancer (BC) that reduce the risk of recurrence and death. They are also known to impact quality-of-life (QoL) during treatment but little is known on their long-term consequences. The main objective is to analyze the impact of these treatments on reported sequelae and QoL 5 years after a diagnosis of BC.
Methods
Data from the French national VICAN5 survey on living conditions of people with cancer 5 years after diagnosis were used. This survey makes available three databases: a patient questionnaire conducted 5 years after diagnosis, a medical questionnaire, and the medical-administrative databases of the French health insurance (SNIIRAM databases). The analyzes were restricted to early BC women. We first modeled ET adherence profiles over the 5 years of ET treatment using the SNIIRAM databases, by applying Group-Based Trajectory Modeling (GBTM) based on the monthly proportion of days covered by ET. Then, we analyze the impact of ET and CHI on QoL and other reported sequelae 5 years after diagnosis, by introducing the ET adherence profiles.
Results
852 women were included in our study, of which 76.4% initiate ET and 53.7% received CHI. A 5-trajectory model of ET adherence profiles was selected, in which: 3 groups described non-persistent profiles, in which they stopped ET long before the recommended duration of treatment, and were therefore merged into a single group (11.3%), 1 group showed a declining adherence (13.2%) and 1 group had an optimal adherence (51.9%). The combination of CHI (yes/no) and ET profiles (no initiation, non-persistence, decline and optimal adherence) resulted in 8 groups of women. These groups presented differences in QoL scores 5 years after diagnosis. Regarding mental QoL, women treated with CHI and belonging to the declining ET group had significantly lower scores of mental QoL compared to the other groups of women.
Conclusions
To date, ET must be taken daily for 5 years, a number of studies have shown its effectiveness but also the benefit of continuing it for another 5 years. The impact of the different treatments on the QoL at a distance from the diagnosis seems to be important.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Presenter Of 1 Presentation
47P - The impact of endocrine therapy and chemotherapy on quality of life 5 years after a breast cancer diagnosis: VICAN5 Survey
Abstract
Background
Endocrine therapy (ET) and chemotherapy (CHI) are among the adjuvant treatments for breast cancer (BC) that reduce the risk of recurrence and death. They are also known to impact quality-of-life (QoL) during treatment but little is known on their long-term consequences. The main objective is to analyze the impact of these treatments on reported sequelae and QoL 5 years after a diagnosis of BC.
Methods
Data from the French national VICAN5 survey on living conditions of people with cancer 5 years after diagnosis were used. This survey makes available three databases: a patient questionnaire conducted 5 years after diagnosis, a medical questionnaire, and the medical-administrative databases of the French health insurance (SNIIRAM databases). The analyzes were restricted to early BC women. We first modeled ET adherence profiles over the 5 years of ET treatment using the SNIIRAM databases, by applying Group-Based Trajectory Modeling (GBTM) based on the monthly proportion of days covered by ET. Then, we analyze the impact of ET and CHI on QoL and other reported sequelae 5 years after diagnosis, by introducing the ET adherence profiles.
Results
852 women were included in our study, of which 76.4% initiate ET and 53.7% received CHI. A 5-trajectory model of ET adherence profiles was selected, in which: 3 groups described non-persistent profiles, in which they stopped ET long before the recommended duration of treatment, and were therefore merged into a single group (11.3%), 1 group showed a declining adherence (13.2%) and 1 group had an optimal adherence (51.9%). The combination of CHI (yes/no) and ET profiles (no initiation, non-persistence, decline and optimal adherence) resulted in 8 groups of women. These groups presented differences in QoL scores 5 years after diagnosis. Regarding mental QoL, women treated with CHI and belonging to the declining ET group had significantly lower scores of mental QoL compared to the other groups of women.
Conclusions
To date, ET must be taken daily for 5 years, a number of studies have shown its effectiveness but also the benefit of continuing it for another 5 years. The impact of the different treatments on the QoL at a distance from the diagnosis seems to be important.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.